Banking of multipotent amniotic fetal stem cells

• US 20050042595A1
• Filed: 08/13/2004
• Published: 02/24/2005
• Est. Priority Date: 08/14/2003
• Status: Abandoned Application

• Current Assignee: Martin Haas
• Original Assignee: Martin Haas
• Inventors: Haas, Martin
• Application Number:
  US10/917,853
• Publication Number:
  US 20050042595A1
• Time in Patent Office: Days
• US Class Current: 435/2
• CPC Class Codes: C12N 2500/25 Insulin-transferrin; Insulin-transferrin-selenium
• CPC Class Codes: C12N 2501/11 Epidermal growth factor [EGF]
• CPC Class Codes: C12N 2501/115 Basic fibroblast growth factor (bFGF, FGF-2)
• CPC Class Codes: C12N 2501/135 Platelet-derived growth factor [PDGF]
• CPC Class Codes: C12N 2501/39 Steroid hormones
• CPC Class Codes: C12N 5/0605 Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
• CPC Class Codes: C12N 5/0607 Non-embryonic pluripotent stem cells, e.g. MASC induced pluripotent stem cells C12N5/0696

Abstract

Stem cells, including those designated as multipotent amniotic fluid stem cells (MAFSC) cells are found in the amniotic fluid of mammals, including humans. MAFSCs are fetal, multipotent stem cells that can be used for any desired stem cell utility, including treatment of individuals in need of tissue replacement or gene therapy. Methods of banking MAFSCs derived from the amniotic fluid cells of pregnant individuals are disclosed. Amniotic fluid-derived cells are banked for the purpose of access to transplantation antigen-compatible or syngeneic multipotent stem cells.

Claims

1. A cell bank system, comprising:

a plurality of preserved, viable samples, containing amniotic fluid-derived cells, wherein said samples are from a plurality of individuals; and

a database containing one or more data fields that allow for specific identification and retrieval of individual samples.

2. The cell bank system of claim 1, wherein said database includes data fields allowing association of an individual sample with a person from whom the sample was obtained.

3. The cell bank system of claim 1, wherein the samples are cryopreserved.

4. The cell bank system of claim 1, wherein individual samples are retrievable by the person from whom the sample was obtained.

5. The cell bank system of claim 1, wherein said samples contain MAFCS.

6. The cell bank system of claim 1, wherein said samples contain amniotic fluid.

7. The cell bank system of claim 1, wherein said samples contain multipotent or pluripotent stem cells.

24. The cell bank system of claim 1, wherein said amniotic fluid-derived cells comprise pluripotent stem cells.

25. The cell bank system of claim 1, wherein said amniotic fluid-derived cells comprise multipotent stem cells characterized by a) the ability to grow in continuous culture for at least 60 generations, and b) the presence of at least one marker selected from the group consisting of:

SSEA3, SSEA4, Tra1-60, Tra1-81, Tra2-54, and Oct-4.

26. The cell bank system of claim 1, wherein said amniotic fluid-derived cells comprise multipotent stem cells characterized by a) the ability to grow in continuous culture for at least 60 generations, and b) the presence of all of the markers SSEA3, SSEA4, Tra1-60, Tra1-81, Tra2-54, and Oct-4.

27. The cell bank system of claim 25 wherein said stem cells are further characterized by expressing at least one marker selected from the group consisting of:

HLA Class I, CD13, CD44, CD49b, and CD105.

28. The cell bank system of claim 1, wherein said amniotic fluid-derived cells comprise pluripotent stem cells characterized by a) the ability to grow in continuous culture for at least 60 generations, and b) the presence of at least one of the markers selected from the group consisting of:

SSEA3, SSEA4, Tra1-60, Tra1-81, Tra2-54, and Oct-4.

29. The cell bank system of claim 1, wherein said amniotic fluid-derived cells comprise pluripotent stem cells characterized by a) the ability to grow in continuous culture for at least 60 generations, and b) the presence of the following markers:

SSEA3, SSEA4, Tra1-60, Tra1-81, Tra2-54, and Oct-4.

30. The cell bank system of claim 29 wherein said stem cells are further characterized by expressing at least one marker selected from the group consisting of:

HLA Class I, CD13, CD44, CD49b, and CD105.

8. A method for banking stem cells, comprising:

obtaining a plurality of viable samples containing amniotic-fluid-derived stem cells, wherein said samples are from the amniotic fluid of a plurality of individual fetuses;

preserving and storing the samples in a manner that preserves viability of at least some of said stem cells;

storing data relating to the identity of individual samples; and

providing for retrieval of said individual samples by or on behalf of the individual from whom the sample was obtained.

9. The method of claim 8, wherein the samples are cryopreserved.

10. The method of claim 8, wherein said samples contain MAFCS.

11. The method of claim 8, wherein said samples contain amniotic fluid.

12. The method of claim 11, wherein said amniotic fluid comprises about 15% to 35% (V/V) of said medium.

13. The method of claim 8, wherein said samples contain multipotent or pluripotent stem cells.

14. A collection comprising a plurality of viable stem cells derived from amniotic fluid of different fetuses.

15. The collection of claim 14, wherein said stem cells are cryopreserved.

16. The collection of claim 14, wherein said cells are fresh cells isolated from amniotic fluid.

17. The collection of claim 14, wherein said cells are cultured MAFSC cells.

18. A method of preparing amniotic fluid derived stem cells (MAFSC) for a potential future use, comprising:

obtaining amniotic fluid containing live cells;

culturing MAFSC cells isolated from said amniotic fluid; and

cryopreserving said MAFSC cells.

19. A storage bank of multiple samples of amniotic fluid-derived cells or MAFSCs taken from multiple individuals, wherein the samples are preserved in such a way as to be viable upon recovery.

20. The storage bank of claim 19, wherein the cells are cryopreserved in a medium comprising DMSO.

21. The storage bank of claim 19, wherein at least some of the samples are differentiable human stem cells.

22. The storage bank of claim 21, wherein said human stem cells are multipotent.

23. The storage bank of claim 21, wherein said human stem cells are pluripotent.